Get started
Author

Marcos Melián

Observed names: M. Melian, M. Melián, Marcos Melian, Marcos Melián-Sosa
ORCID: 0000-0001-6087-0479
Observed ORCID: 0000-0001-6087-0479
OpenAlex ID: A5028113456
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)
2024 · Carles Pericay, Clara Montagut, et al. · Clinical & Translational Oncology · 23
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
2018 · Marcos Melian, David Lorente, et al. · Thoracic Cancer · 21
PDF
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study
2025 · Maribel del Olmo-García, Lorena Hernandez-Rienda, et al. · The Oncologist · 14
Primary Mesenteric Undifferentiated Pleomorphic Sarcoma Masquerading as a Colon Carcinoma: A Case Report and Review of the Literature
2015 · Robert Diaz-Beveridge, Marcos Melian, et al. · Case Reports in Oncological Medicine · 10
PDF
595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
2023 · J. Capdevila Castillon, V. Alonso, et al. · Annals of Oncology · 9
PDF
Abstract B033: Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial
2025 · Moh'd Khushman, Ruth Vera, et al. · Molecular Cancer Therapeutics · 8
Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas
2019 · Carmen Salvador-Coloma, María Saigí, et al. · OncoTargets and Therapy · 7
PDF
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer
2025 · Florian Castet, Carles Fabregat-Franco, et al. · Journal of Hepatology · 6
Phase II study of durvalumab plus total neoadjuvant therapy (TNT) in locally advanced rectal cancer: The GEMCAD-1703 DUREC trial.
2020 · Jaume Capdevila, Ismael Macias Declara, et al. · Journal of Clinical Oncology · 6
Safety and efficacy of encorafenib–cetuximab combination in BRAF-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study
2024 · A. Fernández-Montes, J. Ros, et al. · ESMO Real World Data and Digital Oncology · 5
PDF
Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.
2023 · Ana Fernandez Montes, Javier Ros, et al. · Journal of Clinical Oncology · 5
PDF
Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry
2025 · T. Macarulla, A. Muñoz, et al. · ESMO Real World Data and Digital Oncology · 4
PDF
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study
2024 · Pilar García-Alfonso, Paula Jimenez-Fonseca, et al. · The Oncologist · 4
Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial.
2021 · Carlos Fernandez-Martos, Carles Pericay, et al. · Journal of Clinical Oncology · 3
Long-term responders to trifluridine/tipiracil plus bevacizumab in previously treated metastatic colorectal cancer: Results from the BeTAS real-world study.
2026 · Nieves Martinez Lago, Margarita Reboredo Lopez, et al. · Journal of Clinical Oncology · 1
Real-world efficacy of trifluridine/tipiracil and bevacizumab combination according to baseline prognostic factors: The BeTAS study.
2025 · Nieves Martinez Lago, Maria Carmen Riesco Martinez, et al. · Journal of Clinical Oncology · 1
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
2018 · Juan Antonio Mendez, Domingo Benjamín, et al. · Journal of Clinical Oncology · 1
159P: Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations
2016 · C. Salvador Coloma, O.M. Niño, et al. · Journal of Thoracic Oncology · 1
PDF
145P: Perspectives in oligometastatic brain lesions in non-small cell lung cancer (NSCLC)
2016 · C. Salvador Coloma, C. Escoin Pérez, et al. · Journal of Thoracic Oncology · 1
PDF
Whole-genome sequencing of Reed-Sternberg cells identifies outcome determinants in Hodgkin lymphoma
2026 · Jesús Velasco-Suelto, Laura Gálvez-Carvajal, et al. · Scientific Reports
PDF
Early Plasma Cytokine Profiling Refines Relapse Risk Beyond Interim Pet/Ct in Classical Hodgkin Lymphoma
2026 · Laura Gálvez-Carvajal, Jesús Velasco-Suelto, et al. · Research Square
PDF
Clinical characteristics and survival outcomes of a large cohort of patients diagnosed with diffuse large B-cell lymphoma: Data from the GOTEL Lymphoma Registry.
2026 · Mariola Blanco, Aylen Vanessa Ospina Serrano, et al. · Journal of Clinical Oncology
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study
2026 · Maria Argente-Pla, Miguel Antonio Sampedro-Nuñez, et al. · Frontiers in Nutrition
PDF
1035MO A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs): Results from NUTRIGETNE (GETNE-S2109) study
2025 · M. del Olmo, M.A. Sampedro-Nuñez, et al. · Annals of Oncology
Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutantmetastatic colorectal cancer (mCRC).
2025 · Jeanne Tie, Marcos Melian, et al. · Journal of Clinical Oncology
PDF
Works count: 32
Citation count: 130
H-index: 7
I10-index: 4
Year
Topic
Type